metformin has been researched along with imeglimin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 11 (78.57) | 2.80 |
| Authors | Studies |
|---|---|
| Fouqueray, P; Lebovitz, H; Pirags, V | 1 |
| Bailey, CJ; Diamant, M; Fouqueray, P; Inzucchi, SE; Lebovitz, HE; Pirags, V; Schernthaner, G | 1 |
| Brown, C; Chastain, LM; Maggu, GA; Vuylsteke, V | 1 |
| Fraser-Spears, R; Kim, SS; La-Viola, B; Ramsinghani, S; Sikazwe, D; Witte, AP; Yendapally, R | 1 |
| Bolze, S; Fouqueray, P; Perrimond-Dauchy, S | 1 |
| Borel, AL; Cottet-Rousselle, C; Fontaine, E; Hallakou-Bozec, S; Lamarche, F; Vial, G | 1 |
| Bolze, S; Fontaine, E; Fouqueray, P; Hallakou-Bozec, S; Moller, DE; Monternier, PA; Theurey, P; Vial, G | 1 |
| Arapieva, AM; Bobrik, AG; Bobrik, DV; Khamitova, AD; Kuznetsov, KO; Mahmutova, EI; Nagaev, IR; Saetova, AA | 1 |
| Atsumi, T; Cho, KY; Kameda, H; Kurihara, H; Miya, A; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H; Takahashi, A; Takeuchi, J; Taneda, S | 1 |
| Hozumi, K; Ishihara, N; Ishihara, T; Ogawa, W; Sugawara, K | 1 |
| Atsumi, T; Fujitani, Y; Fukunaka, A; Fukushima, S; Inoue, R; Ito, S; Kyohara, M; Nishiyama, K; Okuyama, T; Ono, M; Sakai, C; Sato, A; Shirakawa, J; Terauchi, Y; Togashi, Y; Tsuno, T; Tsurumoto, A | 1 |
| Ishioh, M; Miyagishi, S; Nozu, T; Okumura, T; Takakusaki, K | 1 |
| Rachdaoui, N | 1 |
| Abe, J; Ando, H; Fujiwara, H; Fujiwara, T; Jing, Z; Maida, Y; Mieda, M; Miura, K; Miyazaki, R; Morishige, JI; Nagata, N; Ono, M; Sakane, N; Shi, Y; Xu, P | 1 |
2 review(s) available for metformin and imeglimin
| Article | Year |
|---|---|
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
Topics: Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Sitagliptin Phosphate; Triazines | 2015 |
A review of phenformin, metformin, and imeglimin.
Topics: Acidosis, Lactic; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Phenformin; Triazines | 2020 |
4 trial(s) available for metformin and imeglimin
| Article | Year |
|---|---|
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Outcome; Triazines; Young Adult | 2012 |
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Triazines; Young Adult | 2013 |
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
Topics: Area Under Curve; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Sitagliptin Phosphate; Triazines | 2020 |
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, p
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
8 other study(ies) available for metformin and imeglimin
| Article | Year |
|---|---|
The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Cells, Cultured; Gluconeogenesis; Hepatocytes; Hypoglycemic Agents; Male; Membrane Potential, Mitochondrial; Metformin; Mitochondria, Liver; Oxidation-Reduction; Oxygen Consumption; Rats, Wistar; Triazines | 2021 |
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Topics: Acidosis, Lactic; Animals; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Agents; Lactic Acid; Metformin; Mice; Rats; Renal Insufficiency; Triazines | 2022 |
[Imeglimin: features of the mechanism of action and potential benefits].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Sitagliptin Phosphate; Triazines | 2022 |
Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes.
Topics: AMP-Activated Protein Kinases; Animals; Gene Expression; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Metformin; Mice; Mitochondria | 2023 |
Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Mice; Mice, Inbred Strains | 2023 |
Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model.
Topics: Animals; Colon; Corticotropin-Releasing Hormone; Irritable Bowel Syndrome; Metformin; Rats | 2023 |
Early Combination Therapies for the Preservation of Pancreatic β Cells in Type 2 Diabetes Mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Insulin-Secreting Cells; Male; Metformin; Mice; Triazines | 2023 |
Imeglimin profoundly affects the circadian clock in mouse embryonic fibroblasts.
Topics: Animals; ARNTL Transcription Factors; Circadian Clocks; Circadian Rhythm; Fibroblasts; Metformin; Mice; Rats; RNA, Messenger | 2023 |